GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Lifeward LFWD · USD

Health Care · US listing · 🇺🇸 United States

Compare

5.94

+2.24%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Lifeward

From its filings with the US Securities and Exchange Commission

SEC filings

Lifeward is based in Hudson, Massachusetts and is incorporated in Israel. Its shares trade on Nasdaq under the ticker LFWD. The SEC classifies its business as orthopedic, prosthetic & surgical appliances & supplies. In the fiscal year to 31 December 2025, it reported revenue of $22.0m and a net loss of $19.9m. At that date it held total assets of $22.9m and shareholders' equity of $8.4m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
12 Sept 2014
Employees
49
Website
rewalk.com ↗
Head office
2 CABOT ROAD, HUDSON, MA, 01749
Incorporated in
L3
Classification
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Joseph TurkIndependent Chairman of the Board
  • Mr. Mark GrantPresident, Chief Executive Officer, Director, since 2025
  • Mr. Almog AdarChief Financial Officer
  • Ms. Jeannine LynchVice President of Market Access and Strategy$381,457
  • Mr. Hadar LevyDirector
  • Mr. Michael SwinfordDirector
  • Mr. Robert MarshallIndependent Director
  • Dr. John PoduskaIndependent Director$94,901
  • Mr. Mike SwinfordIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Leading provider of exoskeleton solutions for individuals with mobility impairments.
  • Established brand in the industry with a strong reputation for innovation and reliability.
  • Extensive intellectual property portfolio, providing a competitive advantage.

Weaknesses

  • High cost of exoskeleton technology limits broader adoption.
  • Relatively limited product range compared to competitors.
  • Dependence on regulatory approvals and reimbursement policies.

Opportunities

  • Increasing global awareness and demand for robotic rehabilitation and assistive devices.
  • Expansion into untapped markets with rising healthcare expenditure and aging populations.
  • Collaborations with healthcare providers and research institutions to further enhance product offerings.

Threats

  • Intense competition from both established companies and startups entering the market.
  • Risk of stricter regulations impacting the approval and reimbursement process.
  • Potential disruption from alternative solutions, such as non-robotic assistive technologies.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.